Evidence map›Paper›PMID 29575763›Full record

ArticleMolecular oncology2018

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34

Stéphanie Maupetit-Mehouas, Franck Court, Céline Bourgne, Agnès Guerci-Bresler, Pascale Cony-Makhoul, Hyacinthe Johnson, Gabriel Etienne, Philippe Rousselot, Denis Guyotat, Alexandre Janel and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Clinical applications of abnormal DNA methylation in chronic myeloid leukemia.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML.Frontiers in cell and developmental biology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Stéphanie Maupetit-MehouasGReD, Université Clermont Auvergne, CNRS, INSERM, Clermont-Ferrand, France.
Franck CourtGReD, Université Clermont Auvergne, CNRS, INSERM, Clermont-Ferrand, France.
Céline BourgneHématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.
Agnès Guerci-BreslerHématologie Clinique, CHRU Nancy, Hôpitaux de Brabois, Vandoeuvre-lès-Nancy, France.
Pascale Cony-MakhoulHématologie Clinique, CH Annecy-Genevois, Epagny Metz-Tessy, France.
Hyacinthe JohnsonInstitut d'Hématologie de Basse Normandie, CHU de Caen, Caen Cedex 9, France.
Gabriel EtienneHématologie Clinique, Institut Bergonié, Bordeaux Cedex, France.
Philippe RousselotCentre Hospitalier de Versailles, service d'Hématologie et d'Oncologie, Le Chesney, France.
Denis GuyotatDépartement d'Hématologie, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
Alexandre JanelHématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.
Eric HermetHématologie Clinique Adulte, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.
Sandrine SauguesHématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.
Juliette BergerHématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.
Philippe ArnaudGReD, Université Clermont Auvergne, CNRS, INSERM, Clermont-Ferrand, France.ORCID 0000-0002-7937-8764
Marc G BergerHématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.
Université Clermont Auvergne · FRCentre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Annecy Genevois · FRCentre Hospitalier de Versailles · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire de Caen Normandie · FRInstitut Bergonié · FRInstitute Cancer De La Loire Lucien Neuwirth · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the high efficiency of tyrosine kinase inhibitors (TKI), some patients with chronic myeloid leukemia (CML) will display residual disease that can become resistant to treatment, indicating intraclonal heterogeneity in chronic-phase CML (CP-CML). To determine the basis of this heterogeneity, we conducted the first exhaustive characterization of the DNA methylation pattern of sorted CP-CML CD34

Indexed as

Transcription, GeneticAdultAgedAged, 80 and overAntigens, CD34CpG IslandsDNA MethylationFemaleGene Expression Regulation, LeukemicGenetic Association StudiesHuman Embryonic Stem CellsHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLewis X AntigenMaleMiddle AgedAntigens, CD34Lewis X AntigenCMLDNA methylationepigeneticsleukemic stem cellstranscriptional defects

Identifiers

PMID29575763
PMCPMC5983208
OpenAlexW2792877077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.